We will obtain cDNAs of the up-regulated proteins previously published: CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PFKCI, and YES (a tyrosine kinase oncogene).
Based on our previous studies, a panel consisting of thirteen protein biomarkers will be used for determining presence or absence of autoantibodies in serum specimen. The 13-protein marker panel consisting of purified full-length recombinant proteins are c-myc, cyclin A, cyclin B1, cyclin D1, CDK2, survivin, CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PRKCI, and YES.
Lung and Upper Aerodigestive Cancers Research Group
We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected lung cancer.
Specific Aim 1. Develop a novel biomarker panel based on our auto-antibody publication and our development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Specific Aim 2. Test the autoantibody panels on CT-scan screen-detected lung cancers including both indolent and aggressive cancers, and validate with thoracic surgery lung cancer cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.” Each lung cancer case will be matched to a control with normal CT scans by smoking, gender, and age.
development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology.
Each sample will be assessed in triplicates, and the average value at 490 nm will be used for data analysis. During the 02 year we will be focusing our efforts at completing the assays and data analysis.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.